Hydrea 500 mg Capsule
Dosage Form | Capsules |
---|---|
Active Ingredients | Hydroxyurea |
Indication | Resistant chronic myeloid leukemia |
Manufacturer | Sarabhai Chemicals |
Packaging | 10 capsules in 1 strip |
Composition | Hydroxyurea (500mg) |
Pack Size | Price | Price/Unit | Quantity | |
---|---|---|---|---|
30 Capsule/s | $25.00 | $0.83 /Piece | Out Of Stock | |
60 Capsule/s | $48.00 | $0.80 /Piece | Out Of Stock | |
90 Capsule/s | $68.00 | $0.76 /Piece | Out Of Stock |
-
FREE SHIPPING ON ALL ORDERS OVER $199
-
100% DELIVERY GUARANTEE
-
TRUSTED BY 10000+ CUSTOMERS
-
BEST PRICE GURENTEED
-
DISCRETE SHIPPING
-
MORE THEN 2000 PRODUCTS
Dosage Form | Capsules |
---|---|
Active Ingredients | Hydroxyurea |
Indication | Resistant chronic myeloid leukemia |
Manufacturer | Sarabhai Chemicals |
Packaging | 10 capsules in 1 strip |
Composition | Hydroxyurea (500mg) |
Description
Description
Hydrea 500 mg Capsule (Hydroxyurea)
Buy Hydrea 500 mg (Hydroxyurea), Acute leukemia, beta thalassaemia, chronic myeloid leukaemia, myeloproliferative disorders, sickle cell anaemia, solid tumor. Hydroxycarbamide causes inhibition of DNA synthesis during the S-phase of cell division by acting as a ribonucleotide reductase inhibitor resulting to cell death. It is S-phase specific.
Acute leukemia, beta thalassaemia, chronic myeloid leukaemia, myeloproliferative disorders, sickle cell anaemia, solid tumor.
Hydroxycarbamide causes inhibition of DNA synthesis during the S-phase of cell division by acting as a ribonucleotide reductase inhibitor resulting to cell death. It is S-phase specific.
erythema, alopecia, hallucination, hyperuricemia, nausea and vomiting, anorexia, chills, disorientation, drowsiness, elevated hepatic enzymes, impaired renal tubular function, dysuria, rashes, Fever, constipation, diarrhea, convulsions., dizziness, stomatitis, increased creatinine, malaise, increased blood urea nitrogen
Reviews (0)
Be the first to review “Hydrea 500 mg Capsule”
You must be logged in to post a review.
Reviews
0 Reviews
There are no reviews yet.